Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Profiling Across 80,000 Patients With Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2026

Russo Alessandro, Javey Manana, Huang Richard S P, Yaung Stephanie J, Kaplan Ben, Hiemenz Matthew C, Arcila Maria E, Lopez-Rios Fernando, Rolfo Christian

Abstract excerpt

INTRODUCTION: Biomarker testing is an essential component of optimal therapeutic management in NSCLC, enabling the use of both Food and Drug Administration-approved and emerging targeted therapies. Despite well-established biomarker testing guidelines and the availability of many approved targeted therapies, a substantial proportion of patients with advanced NSCLC are not benefiting from precision oncology. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ERBB2 gene
Share to ROS1 gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Carcinoma, Non-Small-Cell Lung

Share to Aged, 80 and over

Share to Biomarkers, Tumor

Source

Identifiers

PMID: 41903702
DOI: 10.1016/j.jtho.2026.103695

Genes

EGFR
ALK
BRAF
ERBB2
KRAS
MET
RET
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Profiling Across 80,000 Patients With Lung Cancer.PMID 41903702Read ↗

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read ↗

Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Next-Generation Sequencing Reveals Distinct Molecular Patterns in Lung Cancer: KRAS-Driven Adenocarcinoma and Limited Comutations in EGFR-Mutated TumorsSemantic proximity Read ↗

Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.Semantic proximity Read ↗

Precision medicine and actionable alterations in lung cancer: A single institution experience.Semantic proximity Read ↗

The Impact of Smoking Status on the Genomic Landscape of Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Genomic Landscape of NSCLC in the Republic of IrelandSemantic proximity Read ↗

Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centreSemantic proximity Read ↗

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Semantic proximity Read ↗

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.